NCT04644770 2026-03-13
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
Clinical Trials
5 trialsNCT04943536 2026-02-27
BiolenRT
Alessa Therapeutics Inc.
Phase 1 Active not recruiting
NCT03197571 2025-02-21
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT00643617 2023-05-09
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
Accuray Incorporated
Phase NA Completed
NCT00643994 2023-05-09
CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution
Accuray Incorporated
Phase NA Completed